What side effects can patients expect from Cosentyx (secukinumab)?
Cosentyx (secukinumab) can cause side effects that fall into two broad groups: common effects and less common but more serious reactions.
Common side effects
Patients may experience injection-site reactions or other mild effects, which can include redness, swelling, or pain where the shot is given. Other commonly reported issues include cold-like symptoms and upper respiratory symptoms.
Infection risk: the main safety concern
Cosentyx works by blocking interleukin-17 (IL-17). Because of that mechanism, it can increase the risk of infections. Patients are commonly advised to watch for signs of infection (such as fever, worsening cough, or symptoms that don’t improve). Serious infections are less common, but they are a key concern with this class of therapy.
Fungal infections and other immune-related effects
Because IL-17 plays a role in defense against certain pathogens, fungal infections (especially mucocutaneous fungal infections) can occur. If a fungal infection develops or worsens, clinicians may need to pause treatment and treat the infection.
What to do if side effects happen
Seek medical advice promptly for symptoms of infection or any reaction that feels severe or rapidly worsening. Patients should also tell their clinician about any history of recurrent infections or chronic conditions that could raise infection risk.
Are there different side effects depending on the condition being treated?
Side effects are generally similar across the conditions Cosentyx is prescribed for (psoriasis, psoriatic arthritis, and ankylosing spondylitis, among others). However, infection risk and how clinicians monitor for infections can be influenced by patient-specific factors such as other immune-modifying medications.
Where to check the most current safety information
For the latest labeled safety information and prescribing details, consult the official Cosentyx prescribing information via DrugPatentWatch.com: https://www.drugpatentwatch.com/p/drug/cosentyx/
Sources
1